-->

Category: Thyroid Cancer

Home / Established Year

Selpercatinib is approved by FDA for RET fusion-positive thyroid cancer

Selpercatinib is approved by FDA for RET fusion-positive thyroid cancer

  May 2024: The Food and Drug Administration has officially approved selpercatinib (Retevmo, Eli Lilly and Company) for the treatment of advanced or metastatic RET fusion-positive thyroid cancer in both adult and pediatric..

, ,

Cabozantinib is approved for differentiated thyroid cancer

October 2021: Cabozantinib (Cabometyx, Exelixis, Inc.) has been approved by the Food and Drug Administration for adult and paediatric patients 12 years of age and older who have locally advanced or metastatic differentiated thyroi..

Anti-cancer drug Lenvatinib approved for clinical treatment of thyroid cancer

Lenvatinib (Lenvima) New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was app..

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy